The Fortrea Podcast Wed, 27 May 2026 17:21:57 -0400 https://www.buzzsprout.com/2497579 en-us © 2026 The Fortrea Podcast yes 0b8a8372-b584-583c-a571-7b849402c879 Marina episodic false Buzzsprout (https://www.buzzsprout.com) Marina https://storage.buzzsprout.com/e7nqukm4ygtzzquzciul26wmbqvk?.jpg The Fortrea Podcast Hope in a Dose: CGT Podcast | Ep 11 | CMC Foundations for FIH Success: Getting CGT-Ready from Day Zero Hope in a Dose: CGT Podcast | Ep 11 | CMC Foundations for FIH Success: Getting CGT-Ready from Day Zero In this episode, we focus on building the right CMC foundation for cell and gene therapy success. From manufacturing variability and potency assays to comparability and cold chain logistics, the CMC story is often the story regulators focus on.

Host: Louise Kearney, Head of Cell and Gene Therapy, Strategy and Delivery at Fortrea

Participant: Sanjay Jain, Executive Director of Global Regulatory Affairs Strategy at Fortrea


]]> In this episode, we focus on building the right CMC foundation for cell and gene therapy success. From manufacturing variability and potency assays to comparability and cold chain logistics, the CMC story is often the story regulators focus on.

Host: Louise Kearney, Head of Cell and Gene Therapy, Strategy and Delivery at Fortrea

Participant: Sanjay Jain, Executive Director of Global Regulatory Affairs Strategy at Fortrea


]]> Marina Buzzsprout-19222870 Fri, 22 May 2026 11:00:00 -0400 1042 Clinical Trials, Cell & Gene Therapy, CGT 8 11 full false Cortex Conversations: Insights in Neuroscience | Ep. 6 | Bridging the gap in rare neurological diseases–aligning regulatory expectations with real-world needs Cortex Conversations: Insights in Neuroscience | Ep. 6 | Bridging the gap in rare neurological diseases–aligning regulatory expectations with real-world needs Rare neurological diseases present unique challenges for clinical development, where progress is often limited not only by scientific complexity, but by gaps in meaningful, high-quality data. In this episode of Cortex Conversations, experts explore how aligning regulatory expectations with real-world patient and caregiver needs can help overcome these barriers.

The discussion examines the critical role of natural history data in supporting external control arms and alternative trial designs, while also addressing the burden traditional site-based trials can place on patients—particularly in pediatric and neurodegenerative conditions. Participants share perspectives on emerging hybrid and decentralized approaches, the growing value of patient-driven data, and the collaborative efforts required to build natural history datasets that are both scientifically robust and practical for rare disease communities.

Together, the conversation highlights a path forward for advancing research in rare neurological diseases through innovation, partnership, and patient-centered trial design.

Host: 
Amber Burg, Therapeutic Delivery Head of Neuroscience and Ophthalmology at Fortrea 

Participants 
Louise Kearney, Executive Director of Cell and Gene Therapy at Fortrea

Hannah Simonds, Director of Patient Recruitment and Engagement at Fortrea

Karmen Trzupek, Senior Director of Scientific Programs, Global Genes

]]> Rare neurological diseases present unique challenges for clinical development, where progress is often limited not only by scientific complexity, but by gaps in meaningful, high-quality data. In this episode of Cortex Conversations, experts explore how aligning regulatory expectations with real-world patient and caregiver needs can help overcome these barriers.

The discussion examines the critical role of natural history data in supporting external control arms and alternative trial designs, while also addressing the burden traditional site-based trials can place on patients—particularly in pediatric and neurodegenerative conditions. Participants share perspectives on emerging hybrid and decentralized approaches, the growing value of patient-driven data, and the collaborative efforts required to build natural history datasets that are both scientifically robust and practical for rare disease communities.

Together, the conversation highlights a path forward for advancing research in rare neurological diseases through innovation, partnership, and patient-centered trial design.

Host: 
Amber Burg, Therapeutic Delivery Head of Neuroscience and Ophthalmology at Fortrea 

Participants 
Louise Kearney, Executive Director of Cell and Gene Therapy at Fortrea

Hannah Simonds, Director of Patient Recruitment and Engagement at Fortrea

Karmen Trzupek, Senior Director of Scientific Programs, Global Genes

]]> Marina Buzzsprout-19015857 Tue, 14 Apr 2026 14:00:00 -0400 1569 4 6 full false Accelerating Oncology - Inside the EPON Network | Ep 3 | : Why Location Matters: Country Site Placement Strategy Accelerating Oncology - Inside the EPON Network | Ep 3 | : Why Location Matters: Country Site Placement Strategy In this episode, Why Location Matters: Country and Site Placement Strategy, we explore why geography is more than a backdrop—it is a strategic lever in early phase oncology trials. From patient access and regulatory timelines to investigator expertise and data governance, every decision about trial placement can accelerate or stall innovation.

Join host Maria Garcia and Ken Morrison, as they unpack how Fortrea’s EPON Network optimizes site selection to deliver speed, precision, and confidence in early phase studies.

Host: María García Requesens, Medical Director Fortrea

Participant: Ken Morrison, Global Leader of Strategic Delivery and Growth in Oncology


]]> In this episode, Why Location Matters: Country and Site Placement Strategy, we explore why geography is more than a backdrop—it is a strategic lever in early phase oncology trials. From patient access and regulatory timelines to investigator expertise and data governance, every decision about trial placement can accelerate or stall innovation.

Join host Maria Garcia and Ken Morrison, as they unpack how Fortrea’s EPON Network optimizes site selection to deliver speed, precision, and confidence in early phase studies.

Host: María García Requesens, Medical Director Fortrea

Participant: Ken Morrison, Global Leader of Strategic Delivery and Growth in Oncology


]]> Fortrea Buzzsprout-18761344 Fri, 27 Feb 2026 10:00:00 -0500 701 oncology 11 3 full false Special Topics in Medicine | Ep. 2 | Rare Disease Day Special Topics in Medicine | Ep. 2 | Rare Disease Day Rare diseases are often misunderstood—and Primary Sclerosing Cholangitis (PSC) is no exception.

This Rare Disease Day, join Fortrea and patient advocate leaders to explore why early patient engagement, smarter trial design, and global collaboration are essential to improving outcomes for people living with PSC.

Hear the patient perspective on diagnostic challenges, access to clinical trials, and how patient‑centered research is reshaping the rare disease treatment landscape.

]]> Rare diseases are often misunderstood—and Primary Sclerosing Cholangitis (PSC) is no exception.

This Rare Disease Day, join Fortrea and patient advocate leaders to explore why early patient engagement, smarter trial design, and global collaboration are essential to improving outcomes for people living with PSC.

Hear the patient perspective on diagnostic challenges, access to clinical trials, and how patient‑centered research is reshaping the rare disease treatment landscape.

]]> Marina Buzzsprout-18761187 Fri, 27 Feb 2026 09:00:00 -0500 2435 9 2 full false Hope in a Dose: CGT Podcast | Ep. 10 | Regulatory landscape for ATMPs in EU Hope in a Dose: CGT Podcast | Ep. 10 | Regulatory landscape for ATMPs in EU In this episode, we talk through what sponsors really need to think about when navigating regulatory pathways for cell and gene therapies. We cover everything from early conversations with regulators and managing CMC risk, to using accelerated approval pathways and building a joined‑up regulatory and operational strategy to help get innovative therapies to patients faster. 

]]> In this episode, we talk through what sponsors really need to think about when navigating regulatory pathways for cell and gene therapies. We cover everything from early conversations with regulators and managing CMC risk, to using accelerated approval pathways and building a joined‑up regulatory and operational strategy to help get innovative therapies to patients faster. 

]]> Marina Buzzsprout-18756522 Thu, 26 Feb 2026 14:00:00 -0500 1055 8 10 full false Hope in a Dose: CGT Podcast | Ep. 9 | External Control Arms Hope in a Dose: CGT Podcast | Ep. 9 | External Control Arms In this episode, Fortrea experts discuss how external control arms can enable efficient and ethical cell and gene therapy trials, particularly in rare diseases where traditional control arms are challenging. The conversation highlights study design strategies, regulatory considerations, and how sponsors can use high‑quality external data to accelerate development, reduce patient burden, and support regulatory decision‑making. 

Host: Louise Kearney, Head of Cell and Gene Therapy, Strategy and Delivery at Fortrea

Participant: Christina Wassel, Director of Epidemiology at Fortrea

]]> In this episode, Fortrea experts discuss how external control arms can enable efficient and ethical cell and gene therapy trials, particularly in rare diseases where traditional control arms are challenging. The conversation highlights study design strategies, regulatory considerations, and how sponsors can use high‑quality external data to accelerate development, reduce patient burden, and support regulatory decision‑making. 

Host: Louise Kearney, Head of Cell and Gene Therapy, Strategy and Delivery at Fortrea

Participant: Christina Wassel, Director of Epidemiology at Fortrea

]]> Marina Buzzsprout-18740070 Tue, 24 Feb 2026 10:00:00 -0500 756 8 9 full false Hope in a Dose: CGT Podcast | Ep. 8 | Inside China's Cell & Gene Therapy Boom Hope in a Dose: CGT Podcast | Ep. 8 | Inside China's Cell & Gene Therapy Boom In this episode we focus on one of the most dynamic regions in the CGT space: China. Why is this important? China has roughly become a major hub for cell and gene therapy research, driven by regulatory innovation, technological progress, and significant investment with a large patient population and high unmet medical need.

Host: Louise Kearney, Head of Cell and Gene Therapy, Strategy and Delivery at Fortrea

Participant: Yang Dong, Head of Regulatory Affairs for China at Fortrea

]]> In this episode we focus on one of the most dynamic regions in the CGT space: China. Why is this important? China has roughly become a major hub for cell and gene therapy research, driven by regulatory innovation, technological progress, and significant investment with a large patient population and high unmet medical need.

Host: Louise Kearney, Head of Cell and Gene Therapy, Strategy and Delivery at Fortrea

Participant: Yang Dong, Head of Regulatory Affairs for China at Fortrea

]]> Marina Buzzsprout-18705529 Wed, 18 Feb 2026 08:00:00 -0500 978 8 8 full false Accelerating Oncology - Inside the EPON Network | Ep 2 | Inside the Network: How EPON Builds Strong Site Partnerships Accelerating Oncology - Inside the EPON Network | Ep 2 | Inside the Network: How EPON Builds Strong Site Partnerships In this episode of Accelerating Oncology – Inside the EPON Network, host Maria Garcia discusses why partnerships matter in early phase oncology. We’ll also find out what makes an EPON site different and talk about partnership design principles. 

Host: Maria Garcia, Fortrea Medical Director

Participants: Dr. William McKean, Medical Oncologist and Principal Investigator at The START Center for Cancer Research and Anne Himmel, Senior Manager, Site Engagement and Partnership Delivery at Fortrea

]]> In this episode of Accelerating Oncology – Inside the EPON Network, host Maria Garcia discusses why partnerships matter in early phase oncology. We’ll also find out what makes an EPON site different and talk about partnership design principles. 

Host: Maria Garcia, Fortrea Medical Director

Participants: Dr. William McKean, Medical Oncologist and Principal Investigator at The START Center for Cancer Research and Anne Himmel, Senior Manager, Site Engagement and Partnership Delivery at Fortrea

]]> Marina Buzzsprout-18657399 Tue, 10 Feb 2026 11:00:00 -0500 839 oncology 11 2 full false Accelerating Oncology - Inside the EPON Network | Ep 1 | What EPON Really Means: Accelerating Excellence in Early Phase Oncology Accelerating Oncology - Inside the EPON Network | Ep 1 | What EPON Really Means: Accelerating Excellence in Early Phase Oncology Early Phase Oncology trials have evolved from simple safety checks to the most scientifically demanding stage of cancer drug development. In this episode of Accelerating Oncology – Inside the EPON Network, host Ken Morrison and guest Maria Garcia unpack why Phase 1 trials are no longer “entry-level” and why they require a specialized model for success.

Host: Ken Morrison, Fortrea Global Leader of Strategic Delivery and Growth in Oncology

Participant: Maria Garcia, Fortrea Medical Director

]]> Early Phase Oncology trials have evolved from simple safety checks to the most scientifically demanding stage of cancer drug development. In this episode of Accelerating Oncology – Inside the EPON Network, host Ken Morrison and guest Maria Garcia unpack why Phase 1 trials are no longer “entry-level” and why they require a specialized model for success.

Host: Ken Morrison, Fortrea Global Leader of Strategic Delivery and Growth in Oncology

Participant: Maria Garcia, Fortrea Medical Director

]]> Marina Buzzsprout-18657385 Tue, 10 Feb 2026 11:00:00 -0500 464 oncology 11 1 full false Ophthalmology Perspectives | Ep 3 | Gene Therapy, Patient-Centric Operations, and Risk-Benefit Challenges in Phase 1 Ophthalmology Trials Ophthalmology Perspectives | Ep 3 | Gene Therapy, Patient-Centric Operations, and Risk-Benefit Challenges in Phase 1 Ophthalmology Trials Today we explore the unique challenges and opportunities in Phase 1 ophthalmology clinical trials, focusing on gene therapy and inherited retinal diseases. 

Host: Amber Burg

Participants: David Hoelscher, Senior Medical Director, Ophthalmology 

Tanya Richardson, Therapeutic Strategy Head, Ophthalmology and Neuroscience 

]]> Today we explore the unique challenges and opportunities in Phase 1 ophthalmology clinical trials, focusing on gene therapy and inherited retinal diseases. 

Host: Amber Burg

Participants: David Hoelscher, Senior Medical Director, Ophthalmology 

Tanya Richardson, Therapeutic Strategy Head, Ophthalmology and Neuroscience 

]]> Marina Buzzsprout-18573336 Wed, 04 Feb 2026 00:00:00 -0500 1845 10 3 full false Ophthalmology Perspectives | Ep 2 | Ophthalmology Trials at the Leeds CRU Ophthalmology Perspectives | Ep 2 | Ophthalmology Trials at the Leeds CRU In today’s episode, we delve into the fascinating world of Phase 1 clinical research at Fortrea’s Leeds Clinical Pharmacology Unit in the UK. We explore the operational challenges and innovative solutions behind a recent, complex ophthalmology clinical trial. 

Host: Amber Burg

Participants: Warren Edwicker, Director of Clinic Operations at Fortrea’s Leeds CPU

Natalie Wood, Clinical Research Associate, Leeds UK

]]> In today’s episode, we delve into the fascinating world of Phase 1 clinical research at Fortrea’s Leeds Clinical Pharmacology Unit in the UK. We explore the operational challenges and innovative solutions behind a recent, complex ophthalmology clinical trial. 

Host: Amber Burg

Participants: Warren Edwicker, Director of Clinic Operations at Fortrea’s Leeds CPU

Natalie Wood, Clinical Research Associate, Leeds UK

]]> Marina Buzzsprout-18573323 Wed, 28 Jan 2026 00:00:00 -0500 689 10 2 full false Ophthalmology Perspectives | Ep 1 | Patient Recruitment in Ophthalmology Trials Ophthalmology Perspectives | Ep 1 | Patient Recruitment in Ophthalmology Trials In this conversation today, we're going to dive into the evolving landscape of patient recruitment in ophthalmology and explore how Belite Bio and Fortrea are collaborating to overcome protocol complexities, and discuss the unique opportunities Asia PAC represents for ocular development. We'll also look ahead to the most promising trends shaping the future of ophthalmology trials. 

Host: Amber Burg

Participants: Tanya Richardson Fortrea’s Therapeutic Strategy Head for Neuroscience and Ophthalmology

Lisa Liang, Senior Director of Clinical Operations at Belite Bio. 

]]> In this conversation today, we're going to dive into the evolving landscape of patient recruitment in ophthalmology and explore how Belite Bio and Fortrea are collaborating to overcome protocol complexities, and discuss the unique opportunities Asia PAC represents for ocular development. We'll also look ahead to the most promising trends shaping the future of ophthalmology trials. 

Host: Amber Burg

Participants: Tanya Richardson Fortrea’s Therapeutic Strategy Head for Neuroscience and Ophthalmology

Lisa Liang, Senior Director of Clinical Operations at Belite Bio. 

]]> Marina Buzzsprout-18573291 Mon, 26 Jan 2026 14:00:00 -0500 873 10 1 full false Cortex Conversations: Insights in Neuroscience | Ep 5 | Neuroscience site perspectives on Alzheimer Disease research Cortex Conversations: Insights in Neuroscience | Ep 5 | Neuroscience site perspectives on Alzheimer Disease research Join Leone Atkinson, Fortrea’s Executive Medical Director of Neuroscience and Ophthalmology, and Dr. John Huffaker from the Neuropsychiatric Research Center as they discuss the evolving landscape of Alzheimer’s clinical trials. Explore challenges in patient recruitment and retention, the role of caregivers, and how digital tools and AI are transforming at-home data collection. Learn why collaboration between CROs, sponsors, and research sites is key to advancing patient-centric trial design and improving outcomes.

]]> Join Leone Atkinson, Fortrea’s Executive Medical Director of Neuroscience and Ophthalmology, and Dr. John Huffaker from the Neuropsychiatric Research Center as they discuss the evolving landscape of Alzheimer’s clinical trials. Explore challenges in patient recruitment and retention, the role of caregivers, and how digital tools and AI are transforming at-home data collection. Learn why collaboration between CROs, sponsors, and research sites is key to advancing patient-centric trial design and improving outcomes.

]]> Marina Buzzsprout-18546389 Wed, 21 Jan 2026 08:00:00 -0500 1390 4 5 full false Hope in a Dose: CGT Podcast | Ep. 7 | Long-term Follow Up in Cell and Gene Therapy Trials Hope in a Dose: CGT Podcast | Ep. 7 | Long-term Follow Up in Cell and Gene Therapy Trials In this episode we tackle one of the most critical aspects of these programs: long-term follow-up. Why is it so important? With CAR-T therapies, lentiviral vector-based treatments, and gene editing approaches requiring up to 15 years of follow-up, we’re looking at a rapidly growing population of patients who will need monitoring for years—sometimes decades.

Featuring insights from Gordon Cummings, Global Growth Lead, this episode highlights why long-term follow-up is essential, how sponsors can reduce burden on patients and sites, and the exciting role of data technologies in making these studies more efficient.

]]> In this episode we tackle one of the most critical aspects of these programs: long-term follow-up. Why is it so important? With CAR-T therapies, lentiviral vector-based treatments, and gene editing approaches requiring up to 15 years of follow-up, we’re looking at a rapidly growing population of patients who will need monitoring for years—sometimes decades.

Featuring insights from Gordon Cummings, Global Growth Lead, this episode highlights why long-term follow-up is essential, how sponsors can reduce burden on patients and sites, and the exciting role of data technologies in making these studies more efficient.

]]> Marina Buzzsprout-18476425 Fri, 16 Jan 2026 00:00:00 -0500 1097 8 7 full false Hope in a Dose: CGT Podcast | Ep. 6 | Tumor-Free Territory: Navigating CAR-T in Non-Oncology Landscapes Hope in a Dose: CGT Podcast | Ep. 6 | Tumor-Free Territory: Navigating CAR-T in Non-Oncology Landscapes Expanding cell therapy beyond oncology opens new doors for patients—but it also introduces unique challenges in site identification and startup. From competing studies and resource limitations to regulatory nuances and cross-department collaboration, these hurdles can delay timelines if not addressed early.

In this episode of Hope in a Dose, host Louise Kearney is joined by Erin Jackson and Rielle Giannino to discuss why site selection for CAR-T and other cell therapies is so complex—and how strategic planning and relationship-building can make all the difference.

]]> Expanding cell therapy beyond oncology opens new doors for patients—but it also introduces unique challenges in site identification and startup. From competing studies and resource limitations to regulatory nuances and cross-department collaboration, these hurdles can delay timelines if not addressed early.

In this episode of Hope in a Dose, host Louise Kearney is joined by Erin Jackson and Rielle Giannino to discuss why site selection for CAR-T and other cell therapies is so complex—and how strategic planning and relationship-building can make all the difference.

]]> Marina Buzzsprout-18476405 Thu, 08 Jan 2026 14:00:00 -0500 1072 8 6 full false Hope in a Dose: CGT Podcast | Ep. 5 | Early Phase Challenges in Advanced Therapies Hope in a Dose: CGT Podcast | Ep. 5 | Early Phase Challenges in Advanced Therapies Host: Louise Kearney, Head of Cell and Gene Therapy, Strategy and Delivery at Fortrea

Participant: Frederick Derosier

Description: Cell and gene therapy (CGT) trials are rewriting the rules of early-phase research. Unlike traditional first-in-human studies, these programs involve patients—not healthy volunteers—and often target rare or ultra-rare genetic diseases. That means smaller populations, complex logistics, and long-term follow-up requirements that can span decades.

In this episode of Early Phase Challenges in Advanced Therapies, we explore the unique challenges of designing and delivering early-phase CGT trials—from patient recruitment and dosing to regulatory oversight and global coordination.

]]> Host: Louise Kearney, Head of Cell and Gene Therapy, Strategy and Delivery at Fortrea

Participant: Frederick Derosier

Description: Cell and gene therapy (CGT) trials are rewriting the rules of early-phase research. Unlike traditional first-in-human studies, these programs involve patients—not healthy volunteers—and often target rare or ultra-rare genetic diseases. That means smaller populations, complex logistics, and long-term follow-up requirements that can span decades.

In this episode of Early Phase Challenges in Advanced Therapies, we explore the unique challenges of designing and delivering early-phase CGT trials—from patient recruitment and dosing to regulatory oversight and global coordination.

]]> Marina Buzzsprout-18399348 Sat, 03 Jan 2026 00:00:00 -0500 618 8 5 full false Hope in a Dose: CGT Podcast | Ep. 4 | Patients, Sites, and Speed: Building a Realistic CGT Trial Strategy and Finding the Right Sites Hope in a Dose: CGT Podcast | Ep. 4 | Patients, Sites, and Speed: Building a Realistic CGT Trial Strategy and Finding the Right Sites Host: Louise Kearney, Head of Cell and Gene Therapy, Strategy and Delivery at Fortrea

Participants: 
Andrea Seres, Senior Director of Strategic, Delivery and Growth in Oncology and Gene Therapy, Fortrea
Martin Collins, Director of Global Site Identification, Fortrea

Description: In this episode of podcast series “Hope in a Dose” we discuss the essential elements for successful cell and gene therapy trials: understanding patient eligibility and journey, selecting the right sites, and acting with strategic urgency to accelerate outcomes. Learn how data-driven site selection, operational planning, and collaboration help overcome the unique challenges of CGT studies.

Featuring insights from Andrea Seres and Martin Collins, this episode highlights Fortrea’s proactive approach to supporting sites, optimizing trial placement, and fostering innovation in advanced therapies. Whether you’re a sponsor, investigator, or interested in the future of CGT, you’ll gain practical strategies and real-world perspectives to guide your next steps.

Tune in to discover how thoughtful planning and expertise drive success in cell and gene therapy

]]> Host: Louise Kearney, Head of Cell and Gene Therapy, Strategy and Delivery at Fortrea

Participants: 
Andrea Seres, Senior Director of Strategic, Delivery and Growth in Oncology and Gene Therapy, Fortrea
Martin Collins, Director of Global Site Identification, Fortrea

Description: In this episode of podcast series “Hope in a Dose” we discuss the essential elements for successful cell and gene therapy trials: understanding patient eligibility and journey, selecting the right sites, and acting with strategic urgency to accelerate outcomes. Learn how data-driven site selection, operational planning, and collaboration help overcome the unique challenges of CGT studies.

Featuring insights from Andrea Seres and Martin Collins, this episode highlights Fortrea’s proactive approach to supporting sites, optimizing trial placement, and fostering innovation in advanced therapies. Whether you’re a sponsor, investigator, or interested in the future of CGT, you’ll gain practical strategies and real-world perspectives to guide your next steps.

Tune in to discover how thoughtful planning and expertise drive success in cell and gene therapy

]]> Marina Buzzsprout-18287099 Sat, 13 Dec 2025 00:00:00 -0500 1273 7 4 full false Special Topics in Medicine | Ep. 1 | Redefining Precision Oncology: Imaging Innovations Driving Clinical Trials Special Topics in Medicine | Ep. 1 | Redefining Precision Oncology: Imaging Innovations Driving Clinical Trials In this episode, host Laura Vidal, VP of Oncology at Fortrea, sits down with Dr. Ron Korn, Founder and Chief Medical Officer of Imaging Endpoints, to explore the evolving role of imaging in precision oncology. The conversation covers the latest advancements in molecular imaging, including PSMA PET for prostate cancer and the integration of AI-driven radiomics in clinical trials. The episode highlights how imaging is transforming patient selection, early response identification, and the design of clinical studies.

Listeners will gain an understanding of the challenges and opportunities in aligning imaging with liquid biopsy data, the rise of theranostics, and the regulatory landscape shaping the future of drug development. With practical examples and visionary perspectives, this attachment offers a comprehensive look at how imaging endpoints are driving innovation in oncology and beyond.

If you’re involved in clinical research or interested in the future of medical imaging, this episode—is a must-listen.

]]> In this episode, host Laura Vidal, VP of Oncology at Fortrea, sits down with Dr. Ron Korn, Founder and Chief Medical Officer of Imaging Endpoints, to explore the evolving role of imaging in precision oncology. The conversation covers the latest advancements in molecular imaging, including PSMA PET for prostate cancer and the integration of AI-driven radiomics in clinical trials. The episode highlights how imaging is transforming patient selection, early response identification, and the design of clinical studies.

Listeners will gain an understanding of the challenges and opportunities in aligning imaging with liquid biopsy data, the rise of theranostics, and the regulatory landscape shaping the future of drug development. With practical examples and visionary perspectives, this attachment offers a comprehensive look at how imaging endpoints are driving innovation in oncology and beyond.

If you’re involved in clinical research or interested in the future of medical imaging, this episode—is a must-listen.

]]> Marina Buzzsprout-18287113 Sat, 06 Dec 2025 00:00:00 -0500 1061 9 1 full false Hope in a Dose: CGT Podcast | Ep. 3 | Partners in Scale: CDMOs and CROs Working as One Hope in a Dose: CGT Podcast | Ep. 3 | Partners in Scale: CDMOs and CROs Working as One Host: Louise Kearney, Head of Cell and Gene Therapy, Strategy and Delivery at Fortrea

Participants: 
Jan Skoumal, Head of Delivery for Oncology, Fortrea 
Ludek Sojka, CEO, SCT Bio

Description: In this episode we will discuss topics that are critical to the success of CGT programs: seamless collaboration between CDMOs and CROs. In cell and gene therapy, complexity isn't just in science, it's in the execution. And that's where integrative thinking comes in, where manufacturing and clinical operations work as one, we can accelerate timelines, reduce risk, and optimize costs. In this episode, we'll explore how early alignment between CDMOs and CROs can transform technologies into opportunities, from protocol design to study chain logistics and overall project success. 

Learn how proactive coordination—from tech transfer and manufacturing to clinical operations and regulatory submissions—creates a unified strategy that drives success. Hear real-world insights on overcoming challenges, synchronizing supply chains, and delivering hope to patients faster through true partnership.

]]> Host: Louise Kearney, Head of Cell and Gene Therapy, Strategy and Delivery at Fortrea

Participants: 
Jan Skoumal, Head of Delivery for Oncology, Fortrea 
Ludek Sojka, CEO, SCT Bio

Description: In this episode we will discuss topics that are critical to the success of CGT programs: seamless collaboration between CDMOs and CROs. In cell and gene therapy, complexity isn't just in science, it's in the execution. And that's where integrative thinking comes in, where manufacturing and clinical operations work as one, we can accelerate timelines, reduce risk, and optimize costs. In this episode, we'll explore how early alignment between CDMOs and CROs can transform technologies into opportunities, from protocol design to study chain logistics and overall project success. 

Learn how proactive coordination—from tech transfer and manufacturing to clinical operations and regulatory submissions—creates a unified strategy that drives success. Hear real-world insights on overcoming challenges, synchronizing supply chains, and delivering hope to patients faster through true partnership.

]]> Marina Buzzsprout-18287075 Sat, 06 Dec 2025 00:00:00 -0500 829 7 3 full false Hope in a Dose: CGT Podcast | Ep. 2 | CGT in Pediatric Patient Population Hope in a Dose: CGT Podcast | Ep. 2 | CGT in Pediatric Patient Population Host: Louise Kearney, Head of Cell and Gene Therapy, Strategy and Delivery at Fortrea

Participant: Isabella Presch, Pediatric Clinical Research and Advanced Therapies

Description: Today we're diving into one of the most exciting frontiers in medicine: cell and gene therapy for pediatric diseases. Why is it so important? Part of the answer lies in the fact that cell and gene therapy offers something extraordinary: a cure, not just symptom management. In this episode hear from leading experts about the science, challenges, and human impact of pediatric CGT clinical trials.

Join us as we discuss the evolving landscape, regulatory considerations, and the importance of community support in transforming lives. 

Listen now to “Hope in a Dose” and learn how science is turning hope into reality for children and families worldwide.

]]> Host: Louise Kearney, Head of Cell and Gene Therapy, Strategy and Delivery at Fortrea

Participant: Isabella Presch, Pediatric Clinical Research and Advanced Therapies

Description: Today we're diving into one of the most exciting frontiers in medicine: cell and gene therapy for pediatric diseases. Why is it so important? Part of the answer lies in the fact that cell and gene therapy offers something extraordinary: a cure, not just symptom management. In this episode hear from leading experts about the science, challenges, and human impact of pediatric CGT clinical trials.

Join us as we discuss the evolving landscape, regulatory considerations, and the importance of community support in transforming lives. 

Listen now to “Hope in a Dose” and learn how science is turning hope into reality for children and families worldwide.

]]> Marina Buzzsprout-18287034 Tue, 02 Dec 2025 12:00:00 -0500 898 7 2 full false Hope in a Dose: CGT Podcast | Ep. 1 | What Makes CGT Trials Different? Hope in a Dose: CGT Podcast | Ep. 1 | What Makes CGT Trials Different? Host: Louise Kearney, Head of Cell and Gene Therapy, Strategy and Delivery at Fortrea

Participant: Darby Thomas, Senior Scientific Director for Cell and Gene Therapies, Fortrea 

Description: In this first episode, we're discussing why we should think differently about cell and gene therapy, clinical trials, and the kinds of challenges to conventional trial design, and which means that we have to think about different operation models. 

]]> Host: Louise Kearney, Head of Cell and Gene Therapy, Strategy and Delivery at Fortrea

Participant: Darby Thomas, Senior Scientific Director for Cell and Gene Therapies, Fortrea 

Description: In this first episode, we're discussing why we should think differently about cell and gene therapy, clinical trials, and the kinds of challenges to conventional trial design, and which means that we have to think about different operation models. 

]]> Marina Buzzsprout-18244738 Mon, 24 Nov 2025 11:00:00 -0500 467 7 1 full false Diabetes Dialogues | Ep. 3 | The human side of pediatric Type 1 diabetes Diabetes Dialogues | Ep. 3 | The human side of pediatric Type 1 diabetes Host: Dr. Mala Puri, Senior Medical Director at Fortrea 

Participant: Dr. Sanjoy Dutta PhD, Chief Scientific Officer at Breakthrough T1D

Description: This episode brings together Mala Puri, Senior Medical Director at Fortrea and Dr. Sanjoy Dutta PhD, Chief Scientific Officer to discuss the unique challenges faced by pediatric populations in Type 1 diabetes clinical trials.  

In our previous episode, we explored the scientific foundation behind treating T1D as an autoimmune disease and the critical importance of those first 100 days after diagnosis. In this episode, we shift our focus to the human side of the equation. We'll tackle the real-world hurdles families face when navigating a new T1D diagnosis - from emotional overwhelm to information overload. More importantly, we'll discuss how we can design clinical trials that work for families, not against them, and explore the transformative power of true partnerships between sponsors, CROs, and patient advocacy groups.

]]> Host: Dr. Mala Puri, Senior Medical Director at Fortrea 

Participant: Dr. Sanjoy Dutta PhD, Chief Scientific Officer at Breakthrough T1D

Description: This episode brings together Mala Puri, Senior Medical Director at Fortrea and Dr. Sanjoy Dutta PhD, Chief Scientific Officer to discuss the unique challenges faced by pediatric populations in Type 1 diabetes clinical trials.  

In our previous episode, we explored the scientific foundation behind treating T1D as an autoimmune disease and the critical importance of those first 100 days after diagnosis. In this episode, we shift our focus to the human side of the equation. We'll tackle the real-world hurdles families face when navigating a new T1D diagnosis - from emotional overwhelm to information overload. More importantly, we'll discuss how we can design clinical trials that work for families, not against them, and explore the transformative power of true partnerships between sponsors, CROs, and patient advocacy groups.

]]> Marina Buzzsprout-18091557 Thu, 06 Nov 2025 14:00:00 -0500 1346 6 3 full false Diabetes Dialogues | Ep: 2 | The critical first 100 days for pediatric Type 1 diabetes patients Diabetes Dialogues | Ep: 2 | The critical first 100 days for pediatric Type 1 diabetes patients Host: Dr. Mala Puri, Senior Medical Director at Fortrea 

Participant: Dr. Sanjoy Dutta PhD, Chief Scientific Officer at Breakthrough T1D

Description: This episode brings together Mala Puri, Senior Medical Director at Fortrea and Dr. Sanjoy Dutta PhD Chief Scientific Officer to discuss the unique challenges faced by pediatric populations in Type 1 diabetes clinical trials.  

We explore the specific needs and barriers for children and their families, and the role of advocacy and research groups in supporting them. The conversation highlights practical examples of support programs and tools that can help pediatric patients participate in clinical trials, ensuring their voices are heard and their needs are met. 

]]> Host: Dr. Mala Puri, Senior Medical Director at Fortrea 

Participant: Dr. Sanjoy Dutta PhD, Chief Scientific Officer at Breakthrough T1D

Description: This episode brings together Mala Puri, Senior Medical Director at Fortrea and Dr. Sanjoy Dutta PhD Chief Scientific Officer to discuss the unique challenges faced by pediatric populations in Type 1 diabetes clinical trials.  

We explore the specific needs and barriers for children and their families, and the role of advocacy and research groups in supporting them. The conversation highlights practical examples of support programs and tools that can help pediatric patients participate in clinical trials, ensuring their voices are heard and their needs are met. 

]]> Marina Buzzsprout-18091537 Wed, 05 Nov 2025 15:00:00 -0500 1516 6 2 full false New Era in Obesity Drug Development | Ep. 3 | Body Composition and Muscle Mass: What Matters More - Quantity, Quality, or Both? New Era in Obesity Drug Development | Ep. 3 | Body Composition and Muscle Mass: What Matters More - Quantity, Quality, or Both? Obesity is a serious, chronic disease with multiple health consequences. Effective treatment should go beyond simply reducing body weight. It must focus on decreasing fat mass, improving body composition including preserving muscle mass and enhancing muscle quality addressing associated metabolic comorbidities, and ultimately improving overall quality of life.

Today, scientific advances highlighted by Claudia Filozof and Arya Sharma are reshaping obesity treatment. In this episode, their discussion on body composition explores why both the quantity and quality of muscle mass matter in managing obesity as a chronic disease.

 

Participants:

Host: Claudia Filozof, Vice President and Therapeutic Head Obesity, MASH, and Hepatology at Fortrea

Dr. Arya Sharma, MD, DSc (hon), FRAHS – Emeritus Professor, Thought Leader in Obesity

]]> Obesity is a serious, chronic disease with multiple health consequences. Effective treatment should go beyond simply reducing body weight. It must focus on decreasing fat mass, improving body composition including preserving muscle mass and enhancing muscle quality addressing associated metabolic comorbidities, and ultimately improving overall quality of life.

Today, scientific advances highlighted by Claudia Filozof and Arya Sharma are reshaping obesity treatment. In this episode, their discussion on body composition explores why both the quantity and quality of muscle mass matter in managing obesity as a chronic disease.

 

Participants:

Host: Claudia Filozof, Vice President and Therapeutic Head Obesity, MASH, and Hepatology at Fortrea

Dr. Arya Sharma, MD, DSc (hon), FRAHS – Emeritus Professor, Thought Leader in Obesity

]]> Marina Buzzsprout-18134077 Tue, 04 Nov 2025 15:00:00 -0500 594 5 3 full false Diabetes Dialogues | Ep. 1 | Cracking the T1D cure code: From breakthrough science to breakthrough access Diabetes Dialogues | Ep. 1 | Cracking the T1D cure code: From breakthrough science to breakthrough access Host: Dr. Friedrich Mittermayer, Sr. Medical Director for Endocrinology, Fortrea

Participant: Dr. Esther Latres PhD, VP of Research at Breakthrough T1D

Description: This episode brings together Dr. Friedrich Mittermayer and Dr. Esther Latres PhD, VP of Research, to discuss the exciting cures for T1D, and the challenges those clinical trials face.

This podcast episode explores the urgent realities and untapped opportunities in adult T1D diagnosis and treatment. From the heartbreak of misdiagnosis to the promise of cell and gene therapies, we spotlight the real-world journeys that shape clinical trial access and outcomes. You’ll hear how delayed diagnoses push young adults beyond critical trial windows, why older patients are often overlooked, and how new tools—from EMR pilots to genetic rescores—are helping us find the right patients, faster.

With insights from Breakthrough T1D, we rally around a shared vision: a world without T1D. Because the future of diabetes care isn’t just about innovation—it’s about inclusion.

]]> Host: Dr. Friedrich Mittermayer, Sr. Medical Director for Endocrinology, Fortrea

Participant: Dr. Esther Latres PhD, VP of Research at Breakthrough T1D

Description: This episode brings together Dr. Friedrich Mittermayer and Dr. Esther Latres PhD, VP of Research, to discuss the exciting cures for T1D, and the challenges those clinical trials face.

This podcast episode explores the urgent realities and untapped opportunities in adult T1D diagnosis and treatment. From the heartbreak of misdiagnosis to the promise of cell and gene therapies, we spotlight the real-world journeys that shape clinical trial access and outcomes. You’ll hear how delayed diagnoses push young adults beyond critical trial windows, why older patients are often overlooked, and how new tools—from EMR pilots to genetic rescores—are helping us find the right patients, faster.

With insights from Breakthrough T1D, we rally around a shared vision: a world without T1D. Because the future of diabetes care isn’t just about innovation—it’s about inclusion.

]]> Marina Buzzsprout-18091501 Fri, 31 Oct 2025 05:00:00 -0400 1843 6 1 full false New Era in Obesity Drug Development | Ep. 2 | The Heart of Participation: What Brings Patients to Trials New Era in Obesity Drug Development | Ep. 2 | The Heart of Participation: What Brings Patients to Trials In this episode, we hear from Sarah, a patient living with obesity and a passionate advocate, as she shares her personal experience participating in clinical trials. Sarah reflects on the emotional and practical motivations that drive patients to join studies—from the hope of accessing new treatments to the desire to contribute to scientific progress. She emphasizes the importance of transparency, empathy, and wraparound support in trial design, and how these elements can empower patients to stay engaged.

Sarah also discusses the challenges that can lead to disengagement, such as logistical burdens, unmet expectations, and lack of recognition for non-scale victories. Her insights highlight the need for patient-centric approaches that prioritize quality of life, reduce stigma, and treat obesity as a chronic condition. This episode offers a compelling look into the patient perspective and calls for a reimagining of clinical trial engagement strategies to better serve individuals living with obesity.

]]> In this episode, we hear from Sarah, a patient living with obesity and a passionate advocate, as she shares her personal experience participating in clinical trials. Sarah reflects on the emotional and practical motivations that drive patients to join studies—from the hope of accessing new treatments to the desire to contribute to scientific progress. She emphasizes the importance of transparency, empathy, and wraparound support in trial design, and how these elements can empower patients to stay engaged.

Sarah also discusses the challenges that can lead to disengagement, such as logistical burdens, unmet expectations, and lack of recognition for non-scale victories. Her insights highlight the need for patient-centric approaches that prioritize quality of life, reduce stigma, and treat obesity as a chronic condition. This episode offers a compelling look into the patient perspective and calls for a reimagining of clinical trial engagement strategies to better serve individuals living with obesity.

]]> Marina Buzzsprout-18024427 Sun, 26 Oct 2025 01:00:00 -0400 493 5 2 full false New Era in Obesity Drug Development | Ep. 1 | Breaking the Stigma: Understanding Obesity as a Chronic Disease New Era in Obesity Drug Development | Ep. 1 | Breaking the Stigma: Understanding Obesity as a Chronic Disease In this episode, we hear from Sarah, a patient living with obesity, as she shares her lifelong journey—from early body image struggles and restrictive dieting to participating in a televised weight-loss transformation. Despite achieving peak fitness and completing an Olympic triathlon, Sarah’s weight returned, prompting her to explore the science behind obesity. Her discovery of metabolic adaptation and set-point theory reframed her understanding of the condition—not as a personal failure, but as a complex, chronic disease.

Sarah candidly discusses the lack of empathy and support she received from healthcare professionals, who often dismissed her condition as a lifestyle issue. She calls for a systemic shift in how obesity is perceived and treated—emphasizing the need for education, policy change, and compassionate care. Her story is a powerful reminder that living with obesity is not a choice—and it calls for a significant shift in how we understand, support, and treat this complex, chronic condition.

]]> In this episode, we hear from Sarah, a patient living with obesity, as she shares her lifelong journey—from early body image struggles and restrictive dieting to participating in a televised weight-loss transformation. Despite achieving peak fitness and completing an Olympic triathlon, Sarah’s weight returned, prompting her to explore the science behind obesity. Her discovery of metabolic adaptation and set-point theory reframed her understanding of the condition—not as a personal failure, but as a complex, chronic disease.

Sarah candidly discusses the lack of empathy and support she received from healthcare professionals, who often dismissed her condition as a lifestyle issue. She calls for a systemic shift in how obesity is perceived and treated—emphasizing the need for education, policy change, and compassionate care. Her story is a powerful reminder that living with obesity is not a choice—and it calls for a significant shift in how we understand, support, and treat this complex, chronic condition.

]]> Marina Buzzsprout-18024415 Tue, 21 Oct 2025 01:00:00 -0400 758 5 1 full false Cortex Conversations: Insights in Neuroscience | Ep. 4: From theory to practice - Making digital endpoints deliver Cortex Conversations: Insights in Neuroscience | Ep. 4: From theory to practice - Making digital endpoints deliver Host: Amber Burg, Therapeutic Delivery Head of Neuroscience and Ophthalmology at Fortrea 

Participants: 

Abby Fuller, Senior Director of Strategic Delivery Growth in Neuroscience, Fortrea
 Walter Gonzalez, Associate Director, Digital Health and Innovation, Fortrea
 Haiyan Wei, SVP of Technology and Operations at AI Cure  

Description: From digital endpoint real-world examples to strategic insights, in this episode Fortrea’s Abby Fuller and Walter Gonzalez team up with Haiyan Wei, SVP of Technology and Operations at AI Cure to spotlight how neuroscience trials are turning this digital health innovation into real-world results. We go beyond the buzzwords to explore what’s actually working in the field with digital endpoints, when to invest, and how to choose the right partners. With honest lessons from the front lines and a look at what’s next, this episode is a practical guide for sponsors ready to move from pilot to scale. If you're aiming to make smarter, faster decisions in your neuroscience programs, this is the conversation that connects strategy with execution.

]]> Host: Amber Burg, Therapeutic Delivery Head of Neuroscience and Ophthalmology at Fortrea 

Participants: 

Abby Fuller, Senior Director of Strategic Delivery Growth in Neuroscience, Fortrea
 Walter Gonzalez, Associate Director, Digital Health and Innovation, Fortrea
 Haiyan Wei, SVP of Technology and Operations at AI Cure  

Description: From digital endpoint real-world examples to strategic insights, in this episode Fortrea’s Abby Fuller and Walter Gonzalez team up with Haiyan Wei, SVP of Technology and Operations at AI Cure to spotlight how neuroscience trials are turning this digital health innovation into real-world results. We go beyond the buzzwords to explore what’s actually working in the field with digital endpoints, when to invest, and how to choose the right partners. With honest lessons from the front lines and a look at what’s next, this episode is a practical guide for sponsors ready to move from pilot to scale. If you're aiming to make smarter, faster decisions in your neuroscience programs, this is the conversation that connects strategy with execution.

]]> Marina Buzzsprout-17823693 Fri, 10 Oct 2025 01:00:00 -0400 1894 4 4 full false Pulse Check: The Cardiovascular Conversations | Ep 2: Coronary Imaging Innovation and the Path to Targeted Therapies Pulse Check: The Cardiovascular Conversations | Ep 2: Coronary Imaging Innovation and the Path to Targeted Therapies Host: Dr. Cheerag Shirodaria, VP and Cardiovascular/Metabolic Therapeutic Area Head, Fortrea

Participant: Chris Farina, Abcentra CEO 

Description: In episode two, the conversation turns to clinical development and the power of imaging biomarkers. Dr. Cheerag Shirodaria (Fortrea) and Chris Farina (Abcentra) delve into how innovations in technology and imaging, such as coronary CT angiography (CCTA) and the Fat Attenuation Index (FAI) are transforming risk stratification—reclassifying patients and identifying inflammation even in those with “normal” arteries. The episode also highlights the challenges of trial design in novel populations and the critical role of sponsor-CRO-vendor collaborations, including Fortrea’s CRO support. For pharma teams focused on precision medicine and inflammation-targeted therapies, this episode offers valuable insights into the future of cardiovascular care. 

]]> Host: Dr. Cheerag Shirodaria, VP and Cardiovascular/Metabolic Therapeutic Area Head, Fortrea

Participant: Chris Farina, Abcentra CEO 

Description: In episode two, the conversation turns to clinical development and the power of imaging biomarkers. Dr. Cheerag Shirodaria (Fortrea) and Chris Farina (Abcentra) delve into how innovations in technology and imaging, such as coronary CT angiography (CCTA) and the Fat Attenuation Index (FAI) are transforming risk stratification—reclassifying patients and identifying inflammation even in those with “normal” arteries. The episode also highlights the challenges of trial design in novel populations and the critical role of sponsor-CRO-vendor collaborations, including Fortrea’s CRO support. For pharma teams focused on precision medicine and inflammation-targeted therapies, this episode offers valuable insights into the future of cardiovascular care. 

]]> Marina Buzzsprout-17859856 Fri, 03 Oct 2025 15:00:00 -0400 1233 7 2 full false Cortex Conversations: Insights in Neuroscience | Ep. 3: Digital Endpoints in Neuroscience Today Cortex Conversations: Insights in Neuroscience | Ep. 3: Digital Endpoints in Neuroscience Today Host: Amber Burg, Therapeutic Delivery Head of Neuroscience and Ophthalmology at Fortrea

Participants: 
Leone Atkinson, Executive Medical Director of Neuroscience and Ophthalmology at Fortrea
Alicia Baker, Vice President, Head of Global Regulatory Strategy at Fortrea

Description: Digital endpoints are no longer a future ambition—they’re shaping neuroscience trials today. In this episode, we explore how digital biomarkers are gaining traction, what regulators are saying, and how biotech leaders can confidently integrate these tools into their development strategies. With insights from the Neuroscience team at Fortrea, Amber Burg, Leone Atkinson, and Alicia Baker, we’ll unpack the current landscape, share real-world regulatory wins, and look ahead to what’s next, including AI and hybrid models. Whether you're just starting to explore digital endpoints or looking to push boundaries, this episode lays the groundwork for smarter, more precise neuroscience trials

]]> Host: Amber Burg, Therapeutic Delivery Head of Neuroscience and Ophthalmology at Fortrea

Participants: 
Leone Atkinson, Executive Medical Director of Neuroscience and Ophthalmology at Fortrea
Alicia Baker, Vice President, Head of Global Regulatory Strategy at Fortrea

Description: Digital endpoints are no longer a future ambition—they’re shaping neuroscience trials today. In this episode, we explore how digital biomarkers are gaining traction, what regulators are saying, and how biotech leaders can confidently integrate these tools into their development strategies. With insights from the Neuroscience team at Fortrea, Amber Burg, Leone Atkinson, and Alicia Baker, we’ll unpack the current landscape, share real-world regulatory wins, and look ahead to what’s next, including AI and hybrid models. Whether you're just starting to explore digital endpoints or looking to push boundaries, this episode lays the groundwork for smarter, more precise neuroscience trials

]]> Marina Buzzsprout-17823679 Fri, 03 Oct 2025 15:00:00 -0400 1324 4 3 full false Pulse Check: The Cardiovascular Conversations | Ep 1: Coronary Inflammation—The Next Frontier in Cardiovascular Risk Management  Pulse Check: The Cardiovascular Conversations | Ep 1: Coronary Inflammation—The Next Frontier in Cardiovascular Risk Management  Host: Dr. Cheerag Shirodaria, VP and Cardiovascular/Metabolic Therapeutic Area Head, Fortrea

Participant: Chris Farina, Abcentra CEO 

Description: Despite advances in lipid-lowering and antithrombotic therapies, residual cardiovascular risk remains a major challenge. In this episode, Dr. Cheerag Shirodaria, Fortrea's cardiovascular lead, and Chris Farina, CEO of Abcentra, explore the emerging science behind coronary inflammation as a key driver of atherosclerotic disease. They discuss why inflammation, particularly in vulnerable coronary plaques, is gaining traction as a therapeutic target, and talk about Abcentra’s first-in-class monoclonal antibody - designed to selectively quell inflammation in diseased arterial tissue. With insights from landmark trials, and a look at how these new options differs from systemic anti-inflammatory agents, this episode offers a compelling case for a paradigm shift in cardiovascular drug development. If you're working in CV research, this is a must-listen. 

]]> Host: Dr. Cheerag Shirodaria, VP and Cardiovascular/Metabolic Therapeutic Area Head, Fortrea

Participant: Chris Farina, Abcentra CEO 

Description: Despite advances in lipid-lowering and antithrombotic therapies, residual cardiovascular risk remains a major challenge. In this episode, Dr. Cheerag Shirodaria, Fortrea's cardiovascular lead, and Chris Farina, CEO of Abcentra, explore the emerging science behind coronary inflammation as a key driver of atherosclerotic disease. They discuss why inflammation, particularly in vulnerable coronary plaques, is gaining traction as a therapeutic target, and talk about Abcentra’s first-in-class monoclonal antibody - designed to selectively quell inflammation in diseased arterial tissue. With insights from landmark trials, and a look at how these new options differs from systemic anti-inflammatory agents, this episode offers a compelling case for a paradigm shift in cardiovascular drug development. If you're working in CV research, this is a must-listen. 

]]> Marina Buzzsprout-17859847 Wed, 24 Sep 2025 08:00:00 -0400 1528 7 1 full false Cortex Conversations: Insights in Neuroscience | Ep 2: Innovations in Imaging for Parkinson’s Disease Cortex Conversations: Insights in Neuroscience | Ep 2: Innovations in Imaging for Parkinson’s Disease Host: Amber Burg, Therapeutic Delivery Head of Neuroscience and Ophthalmology at Fortrea

Participants: 
Leone Atkinson, Executive Medical Director of Neuroscience and Ophthalmology, Fortrea
Robin Wolz, Chief Scientific Officer at Ixico 

Description: This episode features an insightful interview between Fortrea neuroscience leaders and experts from Ixico, focusing on novel imaging biomarkers in Parkinson's disease.  

Imaging biomarkers offer valuable insights into Parkinson's disease (PD) progression and can help distinguish it from other conditions. They can be used to identify the disease early, track its progression, and potentially improve clinical care and management.  

We discuss the importance of selecting the right biomarkers and explore various imaging approaches that can enhance the accuracy and effectiveness of clinical trials. Listeners will gain a deeper understanding of how these innovations are shaping the future of neuroscience research. 

]]> Host: Amber Burg, Therapeutic Delivery Head of Neuroscience and Ophthalmology at Fortrea

Participants: 
Leone Atkinson, Executive Medical Director of Neuroscience and Ophthalmology, Fortrea
Robin Wolz, Chief Scientific Officer at Ixico 

Description: This episode features an insightful interview between Fortrea neuroscience leaders and experts from Ixico, focusing on novel imaging biomarkers in Parkinson's disease.  

Imaging biomarkers offer valuable insights into Parkinson's disease (PD) progression and can help distinguish it from other conditions. They can be used to identify the disease early, track its progression, and potentially improve clinical care and management.  

We discuss the importance of selecting the right biomarkers and explore various imaging approaches that can enhance the accuracy and effectiveness of clinical trials. Listeners will gain a deeper understanding of how these innovations are shaping the future of neuroscience research. 

]]> Marina Buzzsprout-17860506 Fri, 19 Sep 2025 01:00:00 -0400 1500 4 2 full false Cortex Conversations: Insights in Neuroscience | Ep. 1: Trust, Tech & Trials Cortex Conversations: Insights in Neuroscience | Ep. 1: Trust, Tech & Trials Host: Amber Burg, Therapeutic Delivery Head of Neuroscience and Ophthalmology at Fortrea

Participants: 
Joanie Brown, Head of Operations at our Rapid Development Studio AI/ML, Fortrea
Mark Austin, CTO at Ixico 

Description: In this episode of the Fortrea neuroscience podcast, we explore how AI is transforming Parkinson’s research—from bold promises to practical breakthroughs. 

Fortrea’s Amber Burg sits down with Joanie Brown, Head of Operations at our Rapid Development Studio AI/ML and Mark Austin, CTO at Ixico, to unpack the evolving role of artificial intelligence in clinical trials. Together, they dive into how AI is being used to enhance imaging, accelerate trial timelines, and improve patient stratification in Parkinson’s disease. 

Listeners will hear real-world examples of AI-powered tools in action - from automated biomarker quantification to predictive modelling - and how these innovations are already delivering measurable gains in trial efficiency. The conversation also tackles the big questions around trust, transparency, and regulatory readiness, offering a candid look at what it takes to build confidence in AI-driven research. 

Whether you're navigating your first AI-enabled trial or scaling your next one, this episode offers practical insights and fresh perspectives from the front lines of neuroscience innovation.

]]> Host: Amber Burg, Therapeutic Delivery Head of Neuroscience and Ophthalmology at Fortrea

Participants: 
Joanie Brown, Head of Operations at our Rapid Development Studio AI/ML, Fortrea
Mark Austin, CTO at Ixico 

Description: In this episode of the Fortrea neuroscience podcast, we explore how AI is transforming Parkinson’s research—from bold promises to practical breakthroughs. 

Fortrea’s Amber Burg sits down with Joanie Brown, Head of Operations at our Rapid Development Studio AI/ML and Mark Austin, CTO at Ixico, to unpack the evolving role of artificial intelligence in clinical trials. Together, they dive into how AI is being used to enhance imaging, accelerate trial timelines, and improve patient stratification in Parkinson’s disease. 

Listeners will hear real-world examples of AI-powered tools in action - from automated biomarker quantification to predictive modelling - and how these innovations are already delivering measurable gains in trial efficiency. The conversation also tackles the big questions around trust, transparency, and regulatory readiness, offering a candid look at what it takes to build confidence in AI-driven research. 

Whether you're navigating your first AI-enabled trial or scaling your next one, this episode offers practical insights and fresh perspectives from the front lines of neuroscience innovation.

]]> Marina Buzzsprout-17828516 Thu, 11 Sep 2025 12:00:00 -0400 1954 4 1 full false Driving Productivity in Biotech Clinical Trials | Ep. 3: Collaboration Between Contract Research Organizations and Biotech Companies Driving Productivity in Biotech Clinical Trials | Ep. 3: Collaboration Between Contract Research Organizations and Biotech Companies In our third episode, we discuss collaboration between Contract Research Organizations and biotech companies, emphasizing the importance of communication and understanding in clinical trials.

Our moderator, Dr. Ken Park, is joined by an exceptional group of speakers: Tracy Newbold, VP of Clinical Operations at Lexicon Pharmaceuticals; Terry Athreya, SVP and Global Head of Clinical Operations for Fortrea; and Alaric Jackson, Chief Technology and Data Officer at Fortrea.

]]> In our third episode, we discuss collaboration between Contract Research Organizations and biotech companies, emphasizing the importance of communication and understanding in clinical trials.

Our moderator, Dr. Ken Park, is joined by an exceptional group of speakers: Tracy Newbold, VP of Clinical Operations at Lexicon Pharmaceuticals; Terry Athreya, SVP and Global Head of Clinical Operations for Fortrea; and Alaric Jackson, Chief Technology and Data Officer at Fortrea.

]]> Marina Buzzsprout-17471619 Mon, 28 Jul 2025 10:00:00 -0400 649 Biotech, Clinical Trials 3 3 full false Driving Productivity in Biotech Clinical Trials | Ep. 2: Innovative Approaches to Enhance Productivity Driving Productivity in Biotech Clinical Trials | Ep. 2: Innovative Approaches to Enhance Productivity This episode explores innovative approaches to enhance productivity within clinical trials, focusing on the use of technology and data-driven strategies.

Our moderator, Dr. Ken Park, is joined by an exceptional group of speakers: Tracy Newbold, VP of Clinical Operations at Lexicon Pharmaceuticals; Terry Athreya, SVP and Global Head of Clinical Operations for Fortrea; and Alaric Jackson, Chief Technology and Data Officer at Fortrea.

]]> This episode explores innovative approaches to enhance productivity within clinical trials, focusing on the use of technology and data-driven strategies.

Our moderator, Dr. Ken Park, is joined by an exceptional group of speakers: Tracy Newbold, VP of Clinical Operations at Lexicon Pharmaceuticals; Terry Athreya, SVP and Global Head of Clinical Operations for Fortrea; and Alaric Jackson, Chief Technology and Data Officer at Fortrea.

]]> Marina Buzzsprout-17471602 Mon, 28 Jul 2025 10:00:00 -0400 1265 Biotech, Clinical Trials 3 2 full false Driving Productivity in Biotech Clinical Trials | Ep. 1: How to Maximize Valuation for Minimal Cost Driving Productivity in Biotech Clinical Trials | Ep. 1: How to Maximize Valuation for Minimal Cost In this episode, “How to Maximize Valuation for Minimal Cost,” we explore a critical question: Are you focused on regulatory approval, or on maximizing value? Your answer could determine the path your clinical trial takes, and the outcome it delivers.

Our moderator, Dr. Ken Park, is joined by an exceptional group of speakers: Tracy Newbold, VP of Clinical Operations at Lexicon Pharmaceuticals; Terry Athreya, SVP and Global Head of Clinical Operations for Fortrea; and Alaric Jackson, Chief Technology and Data Officer at Fortrea.

]]> In this episode, “How to Maximize Valuation for Minimal Cost,” we explore a critical question: Are you focused on regulatory approval, or on maximizing value? Your answer could determine the path your clinical trial takes, and the outcome it delivers.

Our moderator, Dr. Ken Park, is joined by an exceptional group of speakers: Tracy Newbold, VP of Clinical Operations at Lexicon Pharmaceuticals; Terry Athreya, SVP and Global Head of Clinical Operations for Fortrea; and Alaric Jackson, Chief Technology and Data Officer at Fortrea.

]]> Marina Buzzsprout-17471579 Mon, 28 Jul 2025 10:00:00 -0400 1242 Biotech, Clinical Trials 3 1 full false Project Optimus | Ep. 3: Implementing Project Optimus: A Deeper Dive into Modeling, Simulation & Study Design Project Optimus | Ep. 3: Implementing Project Optimus: A Deeper Dive into Modeling, Simulation & Study Design This episode is part of the 'Project Optimus' series exploring oncology trial reform.

Overview: Behind every optimized dose is a robust framework of modeling, simulation, and thoughtful study design. Host Abigail Beanie returns to guide listeners through the technical backbone of Project Optimus. This episode explores how data-driven tools are transforming oncology trials and enabling more precise, patient-centric dosing decisions.

Participants: 

·         Host: Abigail Beanie

·         Dr. Mark Lovern, Executive Director of Medical Science Services, Fortrea 

·         Dr. Richard McNally, Director of Biostatistics, Fortrea

]]> This episode is part of the 'Project Optimus' series exploring oncology trial reform.

Overview: Behind every optimized dose is a robust framework of modeling, simulation, and thoughtful study design. Host Abigail Beanie returns to guide listeners through the technical backbone of Project Optimus. This episode explores how data-driven tools are transforming oncology trials and enabling more precise, patient-centric dosing decisions.

Participants: 

·         Host: Abigail Beanie

·         Dr. Mark Lovern, Executive Director of Medical Science Services, Fortrea 

·         Dr. Richard McNally, Director of Biostatistics, Fortrea

]]> Marina Buzzsprout-17360201 Tue, 08 Jul 2025 09:00:00 -0400 946 Project Optimus, Oncology 2 3 full false Project Optimus | Ep. 2: Operationalizing Project Optimus: Practical Strategies for Smarter Trial Design Project Optimus | Ep. 2: Operationalizing Project Optimus: Practical Strategies for Smarter Trial Design This episode is part of the 'Project Optimus' series exploring oncology trial reform.

Overview: Description:
How do you bring Project Optimus from concept to clinic? In this episode, Dr. Shanthi Sundaramoorthy, Senior Director of Fortrea’s Strategic Growth and Delivery Team in Oncology, shares actionable insights on how sponsors can adapt early-phase trial designs to align with the FDA’s evolving expectations. Learn how smarter dosing strategies can lead to better outcomes and more efficient development.

Participants: 

·         Dr. Shanthi Sundaramoorthy, Senior Director of Fortrea's Strategic Growth and Delivery Team in Oncology, Fortrea 

]]> This episode is part of the 'Project Optimus' series exploring oncology trial reform.

Overview: Description:
How do you bring Project Optimus from concept to clinic? In this episode, Dr. Shanthi Sundaramoorthy, Senior Director of Fortrea’s Strategic Growth and Delivery Team in Oncology, shares actionable insights on how sponsors can adapt early-phase trial designs to align with the FDA’s evolving expectations. Learn how smarter dosing strategies can lead to better outcomes and more efficient development.

Participants: 

·         Dr. Shanthi Sundaramoorthy, Senior Director of Fortrea's Strategic Growth and Delivery Team in Oncology, Fortrea 

]]> Marina Buzzsprout-17360191 Tue, 01 Jul 2025 10:00:00 -0400 505 Project Optimus, Oncology 2 2 full false Project Optimus | Ep. 1: Rethinking Dose Optimization in Oncology Project Optimus | Ep. 1: Rethinking Dose Optimization in Oncology This episode is part of the 'Project Optimus' series exploring oncology trial reform.

Overview: What is Project Optimus, and why is it reshaping the future of oncology drug development? In this kickoff episode, we unpack the FDA’s initiative to modernize dose optimization in cancer trials. Join host Abigail Beanie as she speaks with Audrey Finesso, Senior Director of Clinical Regulatory Strategy, and Luca Cantini, Medical Director of Oncology at Fortrea. Together, they explore the implications for sponsors, regulators, and—most importantly—patients.

Participants: 

·         Host: Abigail Beanie Global Data reporter for Clinical Trials Arena

·         Audrey Finesso, Senior Director of Clinical Regulatory Strategy, Fortrea

·         Luca Cantini, Medical Director, Oncology, Fortrea

]]> This episode is part of the 'Project Optimus' series exploring oncology trial reform.

Overview: What is Project Optimus, and why is it reshaping the future of oncology drug development? In this kickoff episode, we unpack the FDA’s initiative to modernize dose optimization in cancer trials. Join host Abigail Beanie as she speaks with Audrey Finesso, Senior Director of Clinical Regulatory Strategy, and Luca Cantini, Medical Director of Oncology at Fortrea. Together, they explore the implications for sponsors, regulators, and—most importantly—patients.

Participants: 

·         Host: Abigail Beanie Global Data reporter for Clinical Trials Arena

·         Audrey Finesso, Senior Director of Clinical Regulatory Strategy, Fortrea

·         Luca Cantini, Medical Director, Oncology, Fortrea

]]> Marina Buzzsprout-17360183 Fri, 27 Jun 2025 07:00:00 -0400 695 Project Optimus, Oncology 2 1 full false Sustainability in Clinical Trials | Ep 4 | Empowering Partnerships, Part 2 Sustainability in Clinical Trials | Ep 4 | Empowering Partnerships, Part 2 Join us for the fourth episode of our "Sustainability in Clinical Trials" series! 

🎧 This 2-part episode delves into the crucial role of partnerships in challenging established thinking of sustainability and clinical trial design. Host John Kennett is joined by Caleb Tuten, Lisa Moneymaker, Fiona Adshead, and Marlene Knupfer to discuss how organizations can collaborate to share resources and best practices. Discover the benefits of partnerships and what it takes to develop a common language and common goals for sustainability in clinical trials. 🤝

]]> Join us for the fourth episode of our "Sustainability in Clinical Trials" series! 

🎧 This 2-part episode delves into the crucial role of partnerships in challenging established thinking of sustainability and clinical trial design. Host John Kennett is joined by Caleb Tuten, Lisa Moneymaker, Fiona Adshead, and Marlene Knupfer to discuss how organizations can collaborate to share resources and best practices. Discover the benefits of partnerships and what it takes to develop a common language and common goals for sustainability in clinical trials. 🤝

]]> Marina Buzzsprout-17108333 Tue, 10 Jun 2025 08:00:00 -0400 928 1 4 full false Sustainability in Clinical Trials | Ep 3 | Empowering Partnerships, Part 1 Sustainability in Clinical Trials | Ep 3 | Empowering Partnerships, Part 1 Don't miss the third episode of our "Sustainability in Clinical Trials" series! 

🎧 In this 2-part episode, host John Kennett and panelists Caleb Tuten, Lisa Moneymaker, Fiona Adshead, and Marlene Knupfer discuss the vital role of partnerships in driving adoption of sustainable thinking in clinical trial design. They emphasize how organizations across sectors can come together to share resources, knowledge, and best practices, and on what it will take to develop a common language and shared goals for sustainability in clinical trials across our industry. 🌿

]]> Don't miss the third episode of our "Sustainability in Clinical Trials" series! 

🎧 In this 2-part episode, host John Kennett and panelists Caleb Tuten, Lisa Moneymaker, Fiona Adshead, and Marlene Knupfer discuss the vital role of partnerships in driving adoption of sustainable thinking in clinical trial design. They emphasize how organizations across sectors can come together to share resources, knowledge, and best practices, and on what it will take to develop a common language and shared goals for sustainability in clinical trials across our industry. 🌿

]]> Marina Buzzsprout-17108326 Tue, 10 Jun 2025 08:00:00 -0400 1304 1 3 full false Sustainability in Clinical Trials | Ep 2 | Sustainability By Design, Part 2 Sustainability in Clinical Trials | Ep 2 | Sustainability By Design, Part 2 Tune in to the second episode of our "Sustainability in Clinical Trials" series! 

🎧 This 2-part episode delves into how sustainability strategies drive speed and efficiency in drug development. Host John Kennett is joined by Carly Santer, Andrea Robinson-Smith, Ida Corneliusson, Keith Moore, Claire Campbell-Cooper, and Marlene Knupfer to discuss the obstacles slowing progress and share their thoughts on what listeners can do today to make a difference. They also share delightful anecdotes about where things have gone wonderfully right.🌳 

]]> Tune in to the second episode of our "Sustainability in Clinical Trials" series! 

🎧 This 2-part episode delves into how sustainability strategies drive speed and efficiency in drug development. Host John Kennett is joined by Carly Santer, Andrea Robinson-Smith, Ida Corneliusson, Keith Moore, Claire Campbell-Cooper, and Marlene Knupfer to discuss the obstacles slowing progress and share their thoughts on what listeners can do today to make a difference. They also share delightful anecdotes about where things have gone wonderfully right.🌳 

]]> Marina Buzzsprout-17108310 Tue, 10 Jun 2025 08:00:00 -0400 1140 1 2 full false Sustainability in Clinical Trials | Ep 1 | Sustainability By Design, Part 1 Sustainability in Clinical Trials | Ep 1 | Sustainability By Design, Part 1 Dive into our first episode of the "Sustainability in Clinical Trials" series! 

🎧 In this 2-part episode, we explore innovative strategies to drive sustainability and profitability in tandem. Join host John Kennett and our expert panelists Carly Santer, Andrea Robinson-Smith, Ida Corneliusson, Keith Moore, Claire Campbell-Cooper, and Marlene Knupfer as they discuss the current state of sustainability in clinical trials, industry focus areas, and the impact on patients. Discover where progress is being made and how designing clinical trials through the lens of sustainability is making a difference! 🌍

]]> Dive into our first episode of the "Sustainability in Clinical Trials" series! 

🎧 In this 2-part episode, we explore innovative strategies to drive sustainability and profitability in tandem. Join host John Kennett and our expert panelists Carly Santer, Andrea Robinson-Smith, Ida Corneliusson, Keith Moore, Claire Campbell-Cooper, and Marlene Knupfer as they discuss the current state of sustainability in clinical trials, industry focus areas, and the impact on patients. Discover where progress is being made and how designing clinical trials through the lens of sustainability is making a difference! 🌍

]]> Marina Buzzsprout-17108282 Tue, 10 Jun 2025 08:00:00 -0400 1227 1 1 full false Sustainability in Clinical Trials | Ep 6 | The Future of Healthcare, Part 2 Sustainability in Clinical Trials | Ep 6 | The Future of Healthcare, Part 2 Overview: In this 2-part episode, we look a little beyond clinical trials, taking a complex systems view on how sustainability thinking is shaping the future of healthcare as a whole, and the role that our industry must play in informing and promoting this way of thinking. 

Participants: 

·         Host: John Kennett, Director, Global Marketing at Fortrea

·         Jason Laroche, Director of Innovative Health and Environmental Sustainability and Clinical Research at Johnson and Johnson Innovative Medicine

·         Dr. Ashton Harper, Head of Medical Affairs for the UK and Ireland at Roche Diagnostics

·         Emma Iovoli, MD, Lead for Medical Sustainability at Bayer

·         Marlene Knupfer, Instrument and Translation Manager at Fortrea

Part 2: Our panelists continue the discussion of sustainability in healthcare, expanding to carbon tunnel vision, systems thinking, and sharing personal perspectives about what they would do to improve patient outcomes while achieving a greener future. 

]]> Overview: In this 2-part episode, we look a little beyond clinical trials, taking a complex systems view on how sustainability thinking is shaping the future of healthcare as a whole, and the role that our industry must play in informing and promoting this way of thinking. 

Participants: 

·         Host: John Kennett, Director, Global Marketing at Fortrea

·         Jason Laroche, Director of Innovative Health and Environmental Sustainability and Clinical Research at Johnson and Johnson Innovative Medicine

·         Dr. Ashton Harper, Head of Medical Affairs for the UK and Ireland at Roche Diagnostics

·         Emma Iovoli, MD, Lead for Medical Sustainability at Bayer

·         Marlene Knupfer, Instrument and Translation Manager at Fortrea

Part 2: Our panelists continue the discussion of sustainability in healthcare, expanding to carbon tunnel vision, systems thinking, and sharing personal perspectives about what they would do to improve patient outcomes while achieving a greener future. 

]]> Marina Buzzsprout-17306764 Mon, 09 Jun 2025 13:00:00 -0400 991 1 6 full false Sustainability in Clinical Trials | Ep 5 | The Future of Healthcare, Part 1 Sustainability in Clinical Trials | Ep 5 | The Future of Healthcare, Part 1 Overview: In this 2-part episode, we look a little beyond clinical trials, taking a complex systems view on how sustainability thinking is shaping the future of healthcare as a whole, and the role that our industry must play in informing and promoting this way of thinking. 

Participants: 

·         Host: John Kennett, Director, Global Marketing at Fortrea

·         Jason Laroche, Director of Innovative Health and Environmental Sustainability and Clinical Research at Johnson and Johnson Innovative Medicine

·         Dr. Ashton Harper, Head of Medical Affairs for the UK and Ireland at Roche Diagnostics

·         Emma Iovoli, MD, Lead for Medical Sustainability at Bayer

·         Marlene Knupfer, Instrument and Translation Manager at Fortrea

Part 1: Our panelists discuss what a sustainable healthcare model is and provide examples of it in action. They also talk about societal attitude change regarding sustainability from the medical industry and patient perspectives. 

]]> Overview: In this 2-part episode, we look a little beyond clinical trials, taking a complex systems view on how sustainability thinking is shaping the future of healthcare as a whole, and the role that our industry must play in informing and promoting this way of thinking. 

Participants: 

·         Host: John Kennett, Director, Global Marketing at Fortrea

·         Jason Laroche, Director of Innovative Health and Environmental Sustainability and Clinical Research at Johnson and Johnson Innovative Medicine

·         Dr. Ashton Harper, Head of Medical Affairs for the UK and Ireland at Roche Diagnostics

·         Emma Iovoli, MD, Lead for Medical Sustainability at Bayer

·         Marlene Knupfer, Instrument and Translation Manager at Fortrea

Part 1: Our panelists discuss what a sustainable healthcare model is and provide examples of it in action. They also talk about societal attitude change regarding sustainability from the medical industry and patient perspectives. 

]]> Marina Buzzsprout-17306740 Mon, 09 Jun 2025 13:00:00 -0400 1505 1 5 full false